Filter...

AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth CareGeographicals

Select a category...

Myelodysplastic SyndromesMyeloproliferative DisordersJanus Kinase 2Primary MyelofibrosisMyelodysplastic-Myeloproliferative DiseasesPolycythemia VeraThrombocythemia, EssentialSyndromeAnemia, RefractoryLeukemia, Myelomonocytic, ChronicReceptors, ThrombopoietinBone Marrow NeoplasmsAnemia, Refractory, with Excess of BlastsLeukemia, Myeloid, AcuteThrombocytosisLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeLeukemia, MyeloidBone MarrowMutationLeukemia, Myelomonocytic, JuvenileAnemia, SideroblasticChromosomes, Human, Pair 5Proto-Oncogene Proteins c-cblSplenomegalyHematologic NeoplasmsHematopoietic Stem CellsAzacitidineKaryotypingLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrognosisLeukemiaChromosome AberrationsPhiladelphia ChromosomeBlast CrisisDown SyndromeBone Marrow DiseasesHematologyMonosomyPreleukemiaDNA Mutational AnalysisTreatment OutcomeMyeloid Progenitor CellsJanus KinasesThalidomideChromosomes, Human, Pair 7Bone Marrow CellsMegakaryocyte Progenitor CellsMegakaryocytesMetabolic Syndrome XSTAT5 Transcription FactorMegakaryocyte-Erythroid Progenitor CellsMutation, MissenseDisease ProgressionCell Transformation, NeoplasticPancytopeniaAnemia, AplasticChromosome DeletionAcute DiseaseCytogenetic AnalysisClonal EvolutionNeoplasms, Second PrimaryMyelopoiesisAmino Acid SubstitutionPoint MutationFusion Proteins, bcr-ablGene Knock-In TechniquesGranulocyte Precursor CellsProtein Kinase InhibitorsTrisomyHematopoietic Stem Cell TransplantationAntineoplastic AgentsCytogeneticsHematopoiesisProto-Oncogene ProteinsAntimetabolites, AntineoplasticTranslocation, GeneticPhenotypeAntigens, CD34NeoplasmsChromosomes, Human, Pair 8Cell ProliferationNephrotic SyndromeErythropoietinCase-Control StudiesIron OverloadSurvival AnalysisExonsSjogren's SyndromeChromosomes, Human, Pair 20Bone Marrow ExaminationCohort StudiesBlood Cell CountIn Situ Hybridization, FluorescenceRetrospective StudiesErythrocyte TransfusionTransplantation, HomologousHematologic DiseasesThrombocytopeniaHematologic AgentsCore Binding Factor Alpha 2 Subunit

Myeloid neoplasmsAcuteMutationsDisordersLymphomaDiagnosisMPNsOverlapLeukemiaMalignancyGermlineHeterogeneousEntities whoseCancerBloodDiagnosticClinicalPatientsDiseaseDevelopPeopleUnclassifiableMyelofibrosisMyeloidBone marrow failureDiseasesSideroblastsCancersRefractoryStem cellsClinical TrialsTreatmentsMedscapeSpecialistsSymptomsExpertiseIncludeRareResearchPROVIDERSImmuneTests

Myeloid neoplasms4

• Some case reports identified MYC or MLL gene amplification performing as dmin in myeloid neoplasms. (hindawi.com)
• FLT3 ( FMS -related tyrosine kinase 3) acts as an oncogene in myeloid neoplasms which is associated with several signal transduction pathways. (hindawi.com)
• Myelodysplastic syndromes are a group of clonal myeloid neoplasms characterized by ineffective hematopoiesis that present clinically as cytopenia(s), dysplasia in one or more hematopoietic cell lines in the bone marrow, and risk of transformation to acute myeloid leukemia (AML). (medscape.com)
• Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms. (cdc.gov)

Acute6

• Myeloproliferative diseases are a heterogeneous group of disorders characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. (medscape.com)
• Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN) are some of the most common blood cancers in adult patient population. (lls.org)
• The Program for Drug Development in Leukemia offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in phase 1 clinical trials. (mskcc.org)
• Dr. Sallman's research focuses on the development of novel, targeted therapeutic strategies for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (moffitt.org)
• Phase I and II clinical trials) for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) based on the underlying mutational drivers of each disease. (moffitt.org)
• Recently, somatic mutations within SF1 were reported in patients with myelodysplastic syndromes, de novo acute myeloid leukemia and myeloproliferative neoplasms. (fapesp.br)

Mutations4

• The true incidence of somatic mutations in MDS/MPN overlap syndromes remains uncertain, since these syndromes were previously under-diagnosed. (medscape.com)
• SF3B1 has been shown to interact with: CDC5L, DDX42, PPP1R8, SF3B2, SF3B3, SF3B14, Mutations in this gene have been recurrently seen in cases of advanced chronic lymphocytic leukemia, myelodysplastic syndromes and breast cancer. (wikipedia.org)
• Myelodysplastic syndromes are a group of clonal hematopoietic stem cell disorders unified by the presence of distinct mutations of hematopoietic stem cells, most frequently in genes involved in RNA splicing. (msdmanuals.com)
• Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome. (cdc.gov)

Disorders4

• Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes-disorders that include features of both myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN)-are entities whose diagnosis and management have proved challenging. (medscape.com)
• Cytogenetic studies detect the presence or absence of the Philadelphia chromosome and help to differentiate myeloproliferative disorders from myelodysplastic syndrome. (medscape.com)
• Myelodysplastic syndrome is a group of disorders when the blood cells produced in the bone marrow do not mature into healthy cells. (ucsfbenioffchildrens.org)
• Cyclophosphamide increases the risk for bladder cancer, myelodysplastic syndrome, and myeloproliferative disorders. (medscape.com)

Lymphoma1

• The term "blood cancer" encompasses several types of cancer, including leukemia , lymphoma , multiple myeloma , myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). (cancerresearch.org)

Diagnosis2

• For example, no article on paraneoplastic rheumatic syndromes would be complete without a discussion of hypertrophic osteoarthropathy, although it has been about a decade since I last made a diagnosis of a malignancy based on that presentation, perhaps because of the advent of low-dose CT screening of patients with a significant smoking history. (medscape.com)
• RS3PE (remitting seronegative, symmetric synovitis with pitting edema) is another example of a well-established paraneoplastic syndrome, although the majority of patients with this diagnosis do not actually have an associated malignancy . (medscape.com)

MPNs1

• MDS is related to another group of conditions called myeloproliferative neoplasms (MPNs). (myleukemiateam.com)

Overlap3

• The overlap of MDS and MPN features in these syndromes is characterized by presence of cytopenias (due to dysplasia) and increased blood cell counts (due to myeloproliferation)-either or both of which may be present in the same patient. (medscape.com)
• The more rare MDS/MPN overlap syndromes include MDS/MPN with neutrophilia and MDS/MPN, not otherwise specified. (medscape.com)
• This is a multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). (nih.gov)

Leukemia1

• For comparison, we similarly characterize 23 cases with overlapping features of MDS and myeloproliferative neoplasm (MDS/MPN), namely juvenile myelomonocytic leukemia (JMML), and 8 cases of AML with myelodysplasia-related changes (AML-MRC). (nature.com)

Malignancy1

• Sjögren syndrome predisposes to malignancy. (medscape.com)

Germline1

• Despite this progress, no study to date has performed comprehensive sequencing on a pediatric MDS cohort to fully understand somatic and germline variation in this neoplasm. (nature.com)

Heterogeneous1

• [ 1 ] This classification also includes a collection of heterogeneous neoplasms that share features of MDS and myeloproliferative neoplasms. (medscape.com)

Entities whose1

• Myelodysplastic syndromes appear to represent several molecularly unique entities whose variation makes constructing a concise and practical framework difficult. (medscape.com)

Cancer2

• Myelodysplastic syndrome (MDS) is a form of cancer. (ucsfbenioffchildrens.org)
• CRI Technology Impact Award Recipient Muneesh Tewari, MD, PhD (Regents of the University of Michigan), has been working on creating technology that can detect cytokine release syndrome (CRS), a side-effect of CAR T cell treatment where the immune system responds with excessive aggression to cancer. (cancerresearch.org)

Blood2

• If you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. (medlineplus.gov)
• Myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. (medlineplus.gov)

Diagnostic3

• These impediments necessitate the discovery of more objective diagnostic tools-tests for molecular and cytogenetic abnormalities that drive the pathogenesis of these syndromes. (medscape.com)
• Although disease-defining abnormalities have not yet been found, the present knowledge of these aberrations offers better understanding of these neoplasms and can supplement the morphologic and immunophenotypic diagnostic features. (medscape.com)
• Subsequent literature regarding this newly recognized (but of course not truly new) "mast cell activation syndrome" (MCAS) included case reports as well as formal studies (mostly relatively small scale), reviews, and various proposals for formal diagnostic criteria. (degruyter.com)

Clinical1

• Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients. (cdc.gov)

Patients2

• Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. (cdc.gov)
• Then there are patients with paraneoplastic syndromes. (medscape.com)

Disease1

• The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of "mast cell activation syndrome" (MCAS) grown significantly. (degruyter.com)

Develop1

• How Does Myelodysplastic Syndrome Develop? (myleukemiateam.com)

People1

• The number of people diagnosed with myelodysplastic syndromes (MDS) in the United States each year is not known. (msdmanuals.com)

Unclassifiable1

• For full discussion of MDS/MPN, not otherwise specified, see Pathology of Unclassifiable Myelodysplastic Syndromes . (medscape.com)

Myelofibrosis1

• In a small number of patients, the disease may transform to myelofibrosis, acute myeloid leukemia or, less frequently, myelodysplastic syndrome. (lls.org)

Myeloid3

• The panel is comprised of 40 key DNA genes and a broad fusion panel of 29 driver genes (total of 69 genes) to cover the most relevant targets in major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). (umaryland.edu)
• Myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are bone marrow disorders characterized by cytopenias and progression to acute myeloid leukemia. (jcpjournal.org)
• PRIMARY OBJECTIVES: I. To determine the better of two treosulfan-based conditioning regimens in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), by comparing 6-month progression-free survival. (druglib.com)

Bone marrow failure1

• First description of bone marrow failure syndrome in Spain caused by mutations in the ERCC6L2 gene. (amedeo.com)

Diseases1

• Myelodysplastic/myeloproliferative neoplasms are a group of diseases in which the bone marrow makes too many white blood cells. (uamshealth.com)

Sideroblasts1

• The International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) recommended that ring sideroblasts be defined as erythroblasts in which there are a minimum of five siderotic granules covering at least one third of the circumference of the nucleus. (haematologica.org)

Cancers1

• Is one of a related group of blood cancers known as "myeloproliferative neoplasms" (MPNs) in which cells in the bone marrow that produce the blood cells develop and function abnormally. (lls.org)

Refractory1

• Paediatric-onset Evans syndrome: Breaking away from refractory immune thrombocytopenia. (amedeo.com)

Stem cells1

• If you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. (medlineplus.gov)

Clinical Trials1

• Search our clinical trials for those related to Myelodysplastic Syndrome. (uamshealth.com)

Treatments1

• Note that every provider listed below may not perform or prescribe all treatments or procedures related to Myelodysplastic Syndrome. (uamshealth.com)

Medscape1

• Fast Five Quiz: High-Risk Myelodysplastic Syndrome - Medscape - Feb 03, 2021. (medscape.com)

Specialists1

• Compare with other Pancreatic Neoplasms specialists. (healthgrades.com)

Symptoms2

• Myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. (medlineplus.gov)
• Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women. (nih.gov)

Expertise1

• Rush University Medical Center is recognized as a Center of Excellence by the Myelodysplastic Syndrome (MDS) Foundation for its MDS expertise and research. (rush.edu)

Include2

• Myelodysplastic syndromes (MDS) treatment options include supportive care, drug therapy, and chemotherapy with allogeneic stem cell transplant. (uamshealth.com)
• Your treatment plan may include a wide variety of standard treatment options for myelodysplastic syndromes and myeloproliferative neoplasms, including stem cell transplantation . (rush.edu)

Rare3

• Myelodysplastic syndromes are rare. (medlineplus.gov)
• As a Center of Excellence for MDS and myeloproliferative neoplasms, Rush offers advanced, personalized care for these rare blood and bone marrow disorders. (rush.edu)
• Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms are rare stem cell disorders. (rush.edu)

Research1

• What's New in Myelodysplastic Syndrome Research? (medlineplus.gov)

PROVIDERS1

• Rush has myelodysplastic syndromes (MDS) myeloproliferative neoplasms providers in Chicago and Lisle. (rush.edu)

Immune1

• and disorders of the immune system such as severe combined immune deficiencies and Wiskott Aldrich syndrome. (nih.gov)

Tests1

• These impediments necessitate the discovery of more objective diagnostic tools-tests for molecular and cytogenetic abnormalities that drive the pathogenesis of these syndromes. (medscape.com)